Evidence map›Paper›PMID 32936732›Full record

ReviewHuman vaccines & immunotherapeutics2021

Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

Idris Nasir Abdullahi, Anthony Uchenna Emeribe, Hafeez Aderinsayo Adekola, Sharafudeen Dahiru Abubakar, Amos Dangana, Halima Ali Shuwa, Sunday Theophilus Nwoba, Jelili Olaide Mustapha, Muyideen Titilope Haruna, Kafayat Adepeju Olowookere and 13 more

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Antibody-Based Immunotherapeutic Strategies for COVID-19.Pathogens (Basel, Switzerland) · 2020
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 5 countries.

Idris Nasir AbdullahiDepartment of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, Ahmadu Bello University, Zaria, Nigeria.ORCID 0000-0002-5511-1272
Anthony Uchenna EmeribeDepartment of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, Calabar, Nigeria.ORCID 0000-0003-2937-8595
Hafeez Aderinsayo AdekolaDepartment of Microbiology, Olabisi Onabanjo University, Ago-Iwoye, Nigeria.ORCID 0000-0003-3132-3315
Sharafudeen Dahiru AbubakarDepartment of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, Ahmadu Bello University, Zaria, Nigeria.ORCID 0000-0002-2947-589X
Amos DanganaDepartment of Medical Laboratory Services, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria.ORCID 0000-0001-9955-3841
Halima Ali ShuwaLydia Becker Institute of Immunology, Manchester Collaborative Center for Inflammation Research, Faculty of Biology, Medicine and Health, The University of Manchester, UK.ORCID 0000-0002-7926-0360
Sunday Theophilus NwobaDepartment of Chemical and Process Engineering, University of Canterbury, New Zealand.
Jelili Olaide MustaphaBiological Sciences Department, Faculty of Science, University of Alberta, Edmonton, Canada.ORCID 0000-0003-4230-3088
Muyideen Titilope HarunaDepartment of Biology, Dixon Research Center, Morgan State University, Baltimore, USA.
Kafayat Adepeju OlowookereDepartment of Medical Laboratory Services, Ladoke Akintola University of Technology Teaching Hospital, Ogbomoso, Nigeria.
Olawale Sunday AnimasaunNigeria Field Epidemiology and Laboratory Training Programme, African Field Epidemiology Network, Abuja, Nigeria.ORCID 0000-0002-5203-6174
Charles Egede UgwuDepartment of Medical Laboratory Science, Ebonyi State University, Abakaliki, Nigeria.
Solomon Oloche OnojaDepartment of Medical Laboratory Science, University of Nigeria, Enugu, Nigeria.
Abdullahi Sani GadamaDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University, Kano, Nigeria.
Musa MohammedDepartment of Medicine, Immunology Unit, Ahmadu Bello University, Zaria, Nigeria.
Isa Muhammad DanejiDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University, Kano, Nigeria.
Dele Ohinoyi AmaduDepartment of Medical Microbiology and Parasitology, University of Ilorin Teaching Hospital, Ilorin, Nigeria.
Peter Elisha GhambaWHO National Polio Reference Laboratory, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.ORCID 0000-0001-5596-6759
Nkechi Blessing OnukegbeDepartment of Strategic Information and Research, Institute of Human Virology, Abuja, Nigeria.
Muhammad Sagir ShehuMedical Laboratory Department, College of Health Technology, Ningi, Bauchi State, Nigeria.ORCID 0000-0001-9449-5523
Chiladi IsomahMedical Laboratory Science Department, Rivers State University, Port Harcourt, Nigeria.
Adamu BabayoDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University, Kano, Nigeria.ORCID 0000-0003-1039-486X
Abdurrahman El-Fulaty AhmadDepartment of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, Ahmadu Bello University, Zaria, Nigeria.ORCID 0000-0003-1941-8346
Ahmadu Bello University · NGBayero University Kano · NGAfrican Field Epidemiology Network · NGBauchi State University · NGEbonyi State University · NGInstitute of Human Virology · NGLadoke Akintola University of Technology Teaching Hospital · NGMorgan State University · USOlabisi Onabanjo University · NGRivers State University · NGUniversity of Abuja Teaching Hospital · NGUniversity of Alberta · CAUniversity of Calabar · NGUniversity of Canterbury · NZUniversity of Ilorin Teaching Hospital · NGUniversity of Maiduguri · NGUniversity of Manchester · GBUniversity of Nigeria · NG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence and case-fatality rates (CFRs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the etiological agent for Coronavirus Disease 2019 (COVID-19), have been rising unabated. Even though the entire world has been implementing infection prevention and control measures, the pandemic continues to spread. It has been widely accepted that preventive vaccination strategies are the public health measures for countering this pandemic. This study critically reviews the latest scientific advancement in genomics, replication pattern, pathogenesis, and immunopathology of SARS-CoV-2 infection and how these concepts could be used in the development of vaccines. We also offer a detailed discussion on the anticipated potency, efficacy, safety, and pharmaco-economic issues that are and will be associated with candidate COVID-19 vaccines.

Indexed as

AnimalsCOVID-19COVID-19 VaccinesGenomicsHumansPandemicsSARS-CoV-2COVID-19 VaccinesCOVID-19Host-virus interactionSARS-CoV-2Vaccine discovery

Identifiers

PMID32936732
PMCPMC7993231
OpenAlexW3086808711

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.